Novo charts next-phase obesity strategy as Eli Lilly widens lead

Novo Nordisk has outlined a plan to revive growth beyond Wegovy and Ozempic, but investors remain cautious as Eli Lilly continues to strengthen its position in the obesity drug market. The article says Novo is banking on a broader pipeline of future medicines, including new obesity products and treatments outside diabetes and weight loss, as it prepares for patent pressure later this decade. It also faces growing competition from Lilly in both injectable and pillbased GLP1 drugs. Lilly says its obesity pill Foundayo is gaining share in the U.S., while its Zepbound injection has helped it hold a larger share of the broader GLP1 market. Analysts cited in the article argue Lilly has stronger commercial reach, manufacturing advantages, and a deeper pipeline, which could help it keep its lead. Novo, meanwhile, is investing heavily in manufacturing and new drugs such as CagriSema, but it still needs to convince investors that its next generation of products can offset future losses from Wegovy and Ozempic.